Anlon Healthcare Limited (AHCL) Financial Results — Revenue ₹3,330.89 Cr

Investor Takeaways

Revenue declined 69.9% YoY to ₹3,330.89 Cr, with net profit falling 78.6% to ₹354.69 Cr.

Inventory increased by 537.19 lakhs, contributing to margin pressure.

⚠️ No specific risks identified in this filing.

Overall Tone: Cautious based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹3,330.89 Cr	-69.9%
Net Profit	₹354.69 Cr	-78.6%
EBITDA	Not available	N/A
EPS	[amount context mismatch]	N/A
OPM	30.05%	N/A

What Changed

The filing reveals a severe contraction in top-line performance and profitability for Q1 FY26, with revenue dropping to ₹3,330.89 Cr from a significantly higher base in the same quarter last year. Net profit declined by 78.6% to ₹354.69 Cr, indicating substantial margin erosion. The company attributes part of the pressure to a 537.19 lakh increase in inventory, which likely tied up capital and may have led to write-downs or delayed revenue recognition. Additionally, higher operating costs are cited as a contributing factor to the profit decline. The board approved these results on November 11, 2025, following submission of clarification to NSE regarding the financial filings. The company’s current market capitalization stands at ₹709.57 Cr, reflecting diminished investor confidence. The quarterly trend shows improvement from Q4FY26, where revenue was ₹50.89 Cr and profit was ₹11.07 Cr with an OPM of 30.05%, suggesting some recovery momentum quarter-on-quarter, though still far below prior-year levels. Compared to peers, Anlon Healthcare’s financial profile appears weaker, with lower scale and profitability metrics. The company operates in the pharmaceuticals and biotechnology space within the healthcare sector, but current fundamentals indicate operational and financial stress.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Anlon Healthcare Limited (AHCL)	Not available	Not available	Not available	709.57
Sun Pharmaceutical Industries Limited (SUNPHARMA)	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited (DIVISLAB)	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited (TORNTPHARM)	80.06	N/A	N/A	1,49,108.91

Anlon Healthcare’s market capitalization is significantly lower than its peers, reflecting its smaller scale and potentially limited market presence. Its peers demonstrate stronger profitability ratios, with ROE and ROCE indicating efficient use of equity and capital. Valuation metrics like P/E also suggest that the market assigns a premium to larger, more profitable pharmaceutical companies.

Risks & Concerns

Inventory increase of 537.19 lakhs may signal overstocking, obsolescence, or weak demand.

Net profit margin declined sharply despite stable OPM in the prior quarter, suggesting cost or pricing pressures.

No specific risks identified in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q4FY26	50.89	11.07	30.05%

The sequential improvement in revenue and profit from Q4FY26 to Q1FY26 (though still down YoY) suggests possible stabilization, but the scale and magnitude of decline remain concerning.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AHCL ✨ Ask AI About This